Konstantinos Tzortzakis is a Co-Founder and the Chief Business Officer of Anodyne, where since the company’s inception in 2019 he has led pharmaceutical partnerships across multiple modalities and built a pipeline of next-generation cardiometabolic treatments.

An engineer-turned-entrepreneur, Konstantinos holds a Diploma in Electrical and Computer Engineering from the National Technical University of Athens and an M.Sc. in Innovation and Management from Tufts University. He is also one of the key inventors of Anodyne’s proprietary technology.

Jake Lombardo has been Co-Founder and CEO at Anodyne since its inception in early 2019, leading the company through its first successful clinical trial and into clinical development for its lead GLP-1 asset. He brings a unique combination of biomedical engineering expertise and entrepreneurial acumen. Under his leadership, Anodyne has also secured substantial venture capital funding and advanced from concept to a platform company developing multiple, next-generation cardiometabolic treatments.

He holds a B.S. in Biomedical Engineering from Union College and an M.Sc. in Innovation and Management from Tufts University. Jake is also one of the key inventor of Anodyne’s proprietary technology.

James has experience in setting up key operating functions in early-stage companies and delivering strategic analysis projects. Before moving into the medical device industry, James was a medical device investment analyst for more than 8 years, covering the US and European medical device markets at Atlantic Equities and prior to that at US investment bank, Stifel. James has a degree in Biology from the University of Bristol and is a CFA Charterholder.

Terrence Tormey is the Director of Business Development at TSG. His responsibilities are to adapt the Company’s newest UltraSound products for commercial introductions, partnerships, and strategic alliance transactions.

Terrence received a BS degree at St. Vincent College, with additional studies at The Wharton School (The University of Pennsylvania) and The Fuqua School/Duke Law (Duke University).

Mr. Tormey is a Fellow at The American College of Healthcare Trustees. He has extensive experience in introducing new medical devices, pharmaceuticals, and biotech products to the global markets. He has served several stints as CEO at such firms as Xenon-VR, Inc., The Medical Phone Company (a Division of Publicis, Paris), Kibow Biotech, and Omax Health. 

He has launched and or supported dozens of pharmaceuticals, medical devices, and O-T-C healthcare products in the US, and globally, including some of the most iconic medical products (e.g., Aricept®, Cipro®, Imitrex®, Imodium®, Lamictal®, Monistat®, Toprol® XL, Ultram®, Advil®, Tylenol®, Nasacort®, Nicorette®, Primatene®, Refresh®, Replens™, Robitussin® Products, and 60 other products).

At TSG, Mr. Tormey has been instrumental in the introduction of the U-Pen and U-Strip Drug Delivery products. Tormey also has extensive experience in structuring licensing deals with academic tech-transfer offices and major pharmaceutical companies.

Marly Bastiaansen is an experienced pharmaceutical professional with a strong business background and over 10 years of working experience at DFE Pharma, a global leader in excipient solutions. With a solid background in product management, she is dedicated to supporting the development and manufacturing of high-quality medicines through the application of DFE Pharma’s stabilizer solutions.

At this conference, Marly will share her perspective on the role of stabilizers in biopharmaceutical formulations, emphasizing their importance in ensuring product efficacy, safety, and shelf-life.

Bin Zhao, MD, PhD is Scientific Associate Vice-President and Section Head of Thoracic Oncology and Product Development Team lead for Head and Neck Cancer at Merck. Over the past decade, she has held progressively senior roles advancing Keytruda and other oncology programs into global clinical development, including immune-oncology, precision molecular targeting, and tissue targeting therapies.

Dr Zhao received her MD from West China Medical Center, Sichuan University. After completing residency training, she obtained MS in Biochemical Nutrition from Utah State University and PhD in Pharmacology and Cancer Cell Biology from the University of North Carolina at Chapel Hill.

Lilli Zakarija is Co-Founder and President of EdgeOne Medical Inc and has over 25 years of experience in the medical device/combination product industry. Her expertise includes development and global launch of various single-use, disposable medical devices and combination products, strategic/technical development of device platforms and IP management. Throughout her career she has held management roles in engineering and project management, and prior to founding EdgeOne Medical Lilli established and led the global engineering function supporting all device and combination product related needs for the BioScience division of Baxter Healthcare (spun out as Baxalta, then acquired by Shire and subsequently Takeda). Lilli has a Bachelor of Science in Biomedical Engineering and a Master in Engineering Management from Northwestern University, and an Executive MBA from Kellogg School of Management. In addition, Lilli serves on the National Board of Directors for Women in Bio, is an adjunct professor at Northwestern University, a mentor to medical device start-ups in the Chicagoland area and was previously on Board of Advisors for Biomedical Engineering Dept at Northwestern University.

Dr. Latour joined PharmaJet as Chief Executive Officer in 2024. He brings more than 30 years of vaccine and biopharmaceutical industry executive experience to PharmaJet, most recently as CEO, President and Director, and Chairman of the Board at Vaxart, Inc., a clinical stage biotechnology company developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. Previous roles include CEO and Director at Trinity Biosystems, Global Strategy and Business Development roles at Novartis Pharma and SmithKline Beecham Biologicals (now GSK Vaccines), and strategic advisor for several mid-size vaccine companies. Wouter holds Doctor of Medicine and Bachelor’s degrees from the University of Amsterdam and an MBA from Stanford University.